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6 months. The incremental cost-effectiveness ratio (ICER) was determined for 
the cost-effectiveness analysis and comparisons of the three groups with inten-
sive doses (Simvastatin 40 mg/day and Atorvastatin 20-40 mg/day monotherapy 
or combination therapy with Ezetimibe 10 mg) on the provider perspective. The 
direct medical costs were computed by micro-costing method (Reference price in 
2014). The effectiveness was determined by the percentage differences in LDL-C 
reduction. Results: From 250 patients with high risk CHD treated by inten-
sive doses. Sixty-seven, 145 and 38 patients took Simvastatin, Atorvastatin and 
Atorvastatin-Ezetimibe combination, respectively. The outcome determined by the 
percentage differences LDL-C reduction showed that Simvastatin had the lowest 
effectiveness comparing to other groups (mean ± SD; -13.8 ± 32.3%, -28.0 ± 24.8%, 
and -37.8 ± 17.2%, p 0.0001 respectively). ICER determination showed that the 
intensive doses treatment of Atorvastatin had the best result (ICER = 326.91 THB) 
whereas than of Atorvastatin-Ezetimibe combination was poorer (ICER = 732.44 
THB). ConClusions: Comparison of intensive doses Simvastatin, Atorvastatin, 
and Atorvastatin-Ezetimibe combination regimens in second-line treatment 
among high-risk CHD outpatients showed that intensive dose Atorvastatin regi-
men was the most cost-effectiveness.
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objeCtives: Utilizing previously published selection criteria1, identify and evaluate 
current literature that is focused on cost-effectiveness of genotype-guided medica-
tion programs for patients at high risk for a thrombotic event. The aim of study is 
to provide the scientific community with a comprehensive, yet brief overview of 
studies that could inform future development of personalized medicine research 
within this subset of cardiovascular disease. Methods: The literature search was 
conducted within PubMed and Web of Science databases. The objective was to iden-
tify studies published from January 2008 (conclusion period of Vegtar’s research) to 
October 2014 that also included the search term “pharmacogenetic” and the term 
“pharmacoeconomic”. Results: Ten articles met inclusion criteria. Genotypes 
CYP2C19, CYP2C9, VKORC1, KIF6 were used alone and/or in combination within 
differing patient populations. Medication programs included (number of papers): 
Warfarin (4), Clopidgrel (including other in-class agents: 2), phenprocoumon (1), 
atorvastatin/pravastatin (1) and Dabigitran (and other in-class agents: 1). The fol-
lowing types of economic evaluations were utilized either alone or in combination: 
CEA, CUA, CUR, CBA, Threshold Analysis, ICER, ICUR, EA, and INB. Outcome meas-
ures and sensitivity analysis were variable and did not always reach thresholds of 
significance within the overall study population. ConClusions: Comprehensive 
study evaluations were lacking due to inconsistent methodology. Specific study 
guidelines for the field of genotype-guided therapy are needed. With multiple block-
buster medications reaching patent expiry, the cost-effectiveness and sensitivity 
analysis from previous years warrant a second evaluation. It is anticipated that 
genotype-guided treatment may be shifting to a cost-effective option for only the 
treatment-resistant, or smaller populations with a differentiated risk status. This is 
in contrast to selecting genotype-driven therapy as an initial option for the masses 
of patients diagnosed with thrombotic event risk in a more traditional “treat every-
one the same” algorithm. 1Stepfan Vegter et. al, “Pharmacoeconomic Evaluations 
of Pharmacogenetic and Genomic Screening Programmes” Pharmacoeconomics 
2008: 26(7) 569-587.
PCV77
CoSt effeCtiVeneSS of an antiCoaGulant CliniC afteR intRoduCtion 
of noaCS foR StRoke PReVention in atRial fibRillation PatientS in 
the united StateS
Alhazami M.1, Holdford D.A.2
1Virginia Commonwealth University, Glen Allen, VA, USA, 2Virginia Commonwealth University, 
Richmond, VA, USA
objeCtives: To assess cost effectiveness of anticoagulant clinics after FDA approval 
of New Oral Anticoagulants (NOACs) for preventing of ischemic stroke in Atrial 
Fibrillation (AF) patients in the United States. Methods: A decision tree was built 
using outcomes data obtained from randomized clinical trials and publicly available 
cost data. The analysis compared the cost effectiveness of 150mg dabigatran twice 
a day taken with no anticoagulation clinic monitoring versus warfarin titrated to 
dose based upon anticoagulation clinic monitoring. The analysis was for one year 
using an institutional perspective. The population in this analysis was a cohort of 
AF patients, ≥ 65 years old, with a mean CHADS2 score of 2, and no contraindication 
to anticoagulation. The primary outcomes measured were cost in US$ and Quality 
Adjusted Life Year (QALY). All data were subject to sensitivity analyses. Results: 
The base case analysis showed that changing from warfarin to dabigatran without 
monitoring resulting in an additional $251,000 per QALY saved. Sensitivity analyses 
found that the model was sensitive to utilities assigned to outcomes and the prob-
ability of death. ConClusions: NOACs claim to reduce the need for anticoagula-
tion monitoring, thereby competing with anticoagulation clinics. This study showed 
that substituting NOACs for warfarin in this population was not within acceptable 
willingness to pay values for new therapies. It is likely that anticoagulation clinics 
will remain a cost effective option in the near future.
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bACKGRound: Atrial fibrillation (AF) is associated with development of thrombo-
embolic events [1]. The standard therapy used in patients with non-valvular atrial 
fibrillation (NVAF) with risk of stroke is Warfarin. There are new oral anticoagulants 
(NOACs) that also are recommended [2]. objeCtives: Evaluate cost-effectiveness 
of Apixaban compared to Oral Anticoagulants in the prevention of thromboembo-
litic events in NVAF patients from perspective of Guatemala’s Public HealthCare 
System (IGSS). Methods: A Markov decision-analysis model was designed using 
data from clinical trials [3,4,5] (indirect comparisons, where appropriate) to evaluate 
lifetime costs and quality-adjusted life-years (QALY) of Apixaban (5mgBID) in com-
parison to Rivaroxaban (20mg/day) and Warfarin (5mg/day). IGSS used Warfarin and 
Rivaroxaban in NVAF patients. The health states evaluated were: ischemic and hem-
orrhagic strokes, hemorrhagic events (intracranial hemorrhage, other major bleeds 
and clinically relevant non major bleeds), systemic embolism (SE) and myocardial 
infarction (MI). The model population was a hypothetical cohort of 70-year-old NVAF 
patients, suitable to Vitamin K antagonist treatment. Only direct medical costs were 
considerate and taken from IGSS databases from 2014 [6,7]. Outcomes were: overall 
cost, QALY and ICER.  Cost and health outcomes were discounted at 5.0% per year, 
using a lifetime horizon. Results: Apixaban is the only therapy that prevents and 
improved all clinical outcomes. Apixaban prevented: 3 Ischemic Strokes, 14 hemor-
rhagic strokes, 71 hemorrhagic events, 1 MI and 3 SE in comparison to Warfarin. 
Overall costs in a lifetime period per patient were US$9,190; US$11,763; US$12,045 
for Warfarin, Apixaban, and Rivaroxaban respectively.  Apixaban earned the high-
est QALY 5.740; Rivaroxaban reported 5.699 and Warfarin 5.570. Used Warfarin as a 
base, the ICER of Apixaban and Rivaroxaban were US$15,135 and US$21,961 respec-
tively. ConClusions: Neither Apixaban nor Rivaroxaban are Cost-Effectiveness 
therapies in comparison with Warfarin according Guatemala’s 3GPB (US$10,400). 
Among the NOACs currently used by IGSS, Apixaban is shown to be a cost-saving 
therapy in comparison to Rivaroxaban.
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objeCtives: To assess the cost-effectiveness of apixaban for the prevention of 
stroke in patients with non valvular atrial fibrillation (NVAF) from the payer’s 
perspective of the Ministry of Public Healthcare in Ecuador (MPHE). Methods: A 
lifetime Markov model was developed to evaluate the pharmacoeconomic impact 
of apixaban compared to aspirin, warfarin, dabigatran in different dosage (110 
mg and 150 mg) and rivaroxaban, in patients with NVAF and risk of stroke. The 
clinical events considered were: stroke, bleeding, myocardial infarction (MI), car-
diovascular hospitalization (CVH), and treatment discontinuation (TD) of which 
the data was obtained from indirect comparisons, published literature and input 
data from a local expert panel. All costs information 2014 (drug and adverse events) 
was obtained from public data sources of the MPHE. Results: In a Cohort of 
1000 patients with NVAF, apixaban avoided 51 ischemic stokes and 3 bleedings 
vs. aspirin, 4 ischemic stokes, 28 bleedings and 11 related deaths vs. warfarin, 
21 ischemic stokes and 4 related deaths vs. dabigatran 110mg, and 11 ischemic 
strokes, 28 bleedings and 5 related deaths vs. dabigatran 150mg and 7 ischemic 
stokes, 7 bleedings and 6 related deaths vs. rivaroxaban. Apixaban was associated 
with 0.324 life years (LYG) and 0.0.273 quality-adjusted life-years (QALYs) gain 
when compared to aspirin, 0.181 LYG and 0.190 QALYs gain compared to warfarin, 
0.123 LYG and 0.106 QALYs gain when compared to dabigatran 110mg, 0.081 LYG 
and 0.07 QALYs gained compared to dabigatran 150mg and 0.059 LYG and 0.048 
QALYs gained compared to rivaroxaban. Apixaban was more effective and less 
costly (dominant) than dabigatran 110mg and dabigatran 150mg and cost-effective 
alternative compared with aspirin, warfarin and rivaroxaban. ConClusions: 
Apixaban is a cost effective or dominant alternative compared with treatment 
options for the prevention of stroke in patients with NVAF from the payer’s per-
spective of the Ecuadorian Ministry of public healthcare.
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objeCtives: Current studies have recommended intensive doses of statins in 
patients with diabetes or cardiovascular disease. In general practice, standard 
dose statins, which used to be effective treatment may not be good enough. 
Furthermore, the cost-effectiveness studies have not concerned about this prob-
lem that may be an important factor in cost-effectiveness analysis. The pur-
pose of this study was to determine the cost-effectiveness of intensive doses of 
Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe combination among high-
risk CHD outpatients in second-line treatments. Methods: A cross-sectional ret-
rospective study in high-risk CHD outpatients was performed at the Chandrubeksa 
Hospital Medical Department of the Royal Thai Air Force, Thailand. Data collection 
was done by computerization combined with reviewing medical record during 
